Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.
Quercetin + Dasatinib
Also known as: D+Q, Senolytic Stack, Dasatinib + Quercetin
The combination of dasatinib (a tyrosine kinase inhibitor cancer drug) and quercetin (a plant flavonoid) is the most studied senolytic regimen. Pioneered by Drs. Kirkland and Tchkonia at Mayo Clinic, this combination selectively clears senescent cells and has shown benefits in multiple human pilot studies for age-related conditions.
Risk Level
Medium RiskDifficulty
Advanced| Class | Other |
| Category | Longevity Compounds |
Mechanism of Action
Dasatinib targets senescent preadipocytes by inhibiting multiple tyrosine kinases in the pro-survival SCAP (senescent cell anti-apoptotic pathway) network, including SRC kinase, ephrin receptors, and BCL-XL. Quercetin targets senescent endothelial cells and other cell types by inhibiting PI3K, serpines, and BCL-2. Together, they cover a broader range of senescent cell types than either compound alone.
Dosing Research
Research protocol: Dasatinib 100 mg + Quercetin 1000-1250 mg for 3 consecutive days, repeated monthly or every 3 months. This intermittent dosing is sufficient because senescent cells do not regenerate quickly. Dasatinib requires a prescription. Quercetin is available over-the-counter. Must be supervised by a physician due to dasatinib.
Side Effects & Risks
Quercetin is well-tolerated. Dasatinib carries risks including fluid retention, nausea, diarrhea, myelosuppression, pleural effusion, and QT prolongation. Intermittent low-dose use appears much safer than chronic oncology dosing. Blood counts should be monitored. Not appropriate for self-experimentation due to dasatinib prescription requirement and side effect profile.
Research Studies
Related compounds
Finasteride
OtherFinasteride is a selective type II 5-alpha reductase inhibitor approved for male pattern hair loss (1 mg, Propecia) and benign prostatic hyperplasia (5 mg, Proscar). It reduces scalp DHT levels by approximately 60-70% and is one of only two FDA-approved oral medications for androgenetic alopecia. It has decades of clinical data supporting its efficacy.
Tamoxifen
OtherTamoxifen is a selective estrogen receptor modulator (SERM) that has been the gold standard for breast cancer treatment and prevention since the 1970s. It is one of the most widely used compounds in post-cycle therapy (PCT) for restoring endogenous testosterone production after anabolic steroid use.
Clomiphene Citrate
OtherClomiphene citrate is a SERM originally developed for female ovulation induction and widely adopted in PCT protocols and off-label male hypogonadism treatment. It is a racemic mixture of two geometric isomers, enclomiphene (trans) and zuclomiphene (cis), with differing estrogenic properties.
Anastrozole
OtherAnastrozole is a potent, selective non-steroidal aromatase inhibitor that reduces estradiol levels by approximately 80-85%. It is widely used in breast cancer treatment and is the most commonly employed AI during anabolic steroid cycles to manage estrogen-related side effects.
Disclaimer
CompoundIQ publishes research summaries for informational and educational purposes only. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. Always consult a licensed healthcare provider. Many compounds listed are research chemicals not approved for human use.